GPC3 targeting CAR-T cells
/ Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 18, 2019
GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
(clinicaltrials.gov)
- P1; N=30; Recruiting; Sponsor: Second Affiliated Hospital of Guangzhou Medical University; Trial primary completion date: Aug 2019 ➔ Aug 2020
Clinical • Trial primary completion date
1 to 1
Of
1
Go to page
1